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Objective. To analyze patterns and frequency of recurrences of squamous cell carcinoma (SCC) of the vulva after wide local excision (WLE)
and superficial inguinal lymphadenectomy with separate incisions and to identify prognostic factors for the development of recurrences.
Methods. Between January 1985 and December 1999, all 125 consecutive patients with primary SCC of the vulva, treated with WLE and
superficial inguinal lymphadenectomy, were retrospectively analyzed. Recurrences were registered by localization as: local, skin bridge, groin or
distant.
Results. A local recurrence was diagnosed in 29 (23%) patients, 11 (9%) developed a groin and 4 (3%) a distant recurrence. No skin bridge
recurrences were identified. The 5 years local relapse-free survival was 70%. After a first local recurrence, 72% of these patients developed a
second local recurrence. Adjusted for other predictors, older age (>74 years) is an independent risk factor for local recurrences (HR: 2.38; 95%-C.
I.: 1.08–5.23) and stage III/IV cancer for developing groin/distant recurrences (HR: 3.03; 95%-C.I.: 1.0–9.18).
Conclusion. WLE and superficial inguinal lymphadenectomy with separate incisions result in a high groin recurrence rate in this study;
superficial lymphadenectomy should be replaced by deep inguinofemoral lymphadenectomy. After a local recurrence, 72% of the patients
developed a second local recurrence. These patients are at high risk and need a close follow-up.
© 2006 Elsevier Inc. All rights reserved.Keywords: Vulvar carcinoma; Local recurrences; Groin recurrence; Skin bridge recurrences; Progression-free survival; Local relapse-free survivalBackground
Vulvar cancer is a rare malignancy, representing about 4% of
the malignancies of the female genital tract [1]. The incidence is
2.1 per 100,000 women in South Australia [2]. In the early
1950s, Stanley Way introduced the radical vulvectomy with “en
bloc” bilateral inguinofemoral lymphadenectomy as standard
treatment for all operative vulvar cancers [3 4]. This strategy
resulted in excellent survival rates up to 90% 5-year survival for
patients without lymph node metastases (stages I and II) and an⁎ Corresponding author. Fax: +31 50 3611806.
E-mail address: m.j.e.mourits@og.umcg.nl (M.J.E. Mourits).
0090-8258/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.ygyno.2006.03.010overall survival rate of about 70% [1,4]. However, the
complication rate was high because of the extension of the
operation. Major early complications were infections and
wound breakdown [5]. The major late postoperative complica-
tion was chronic leg edema. Other complications were
erysipelas, urinary stress incontinence and significant distur-
bances of sexual function and body image [1].
Since 1985, major modifications have been introduced to
the standard surgical treatment to reduce morbidity without
compromising the prognosis. These modifications are: wide
local excision instead of radical vulvectomy, no lymph node
dissection in case of a micro-invasive tumor (invasion
<1 mm), unilateral lymph node dissection in case of a lateral
294 J.M. Woolderink et al. / Gynecologic Oncology 103 (2006) 293–299tumor (a unilateral lesion with the medial margin >1 cm from
the midline, provided that the contralateral side of the vulva is
histological-free from a second primary tumor) [6] and either
superficial or deep inguinal lymphadenectomy by separate
incisions in stead of en bloc inguinofemoral lymph node
excision. In 1985, this new treatment, WLE and superficial
lymph node dissection, has been introduced in South Australia.
The new standard treatment, consisting of wide local
excision with uni- or bilateral lymph node dissection by
separate incisions, has never been investigated as far as we
know in randomized studies, although several studies evaluated
the new technique retrospectively [7–9].
A potential disadvantage of separate incisions is the possible
occurrence of skin bridge recurrences. The mechanism of
lymphatic spread in vulvar cancer is by embolization rather than
by permeation. Therefore, the possibility of leaving tumor
emboli in efferent lymphatics in the tissue bridge between the
vulvar and the groin resections must be considered [5]. The
typical occurrence of a skin bridge recurrence shortly after
primary therapy in a patient with nodal metastasis suggests that
this may represent retrograde permeation of emboli in lymphatic
channels in patients with nodal metastases [10]. However, skin
bridge recurrences have also been described in patients with
negative lymph nodes [10]. Skin bridge recurrences are nearly
always fatal [8,11].
The most common site of recurrence for vulvar cancer is the
vulvar region [12]. It also may be a second primary tumor
(tumor de novo) especially in patients with premalignant vulvar
disease. Groin recurrences develop mostly earlier than vulvar
recurrences or second primaries, and the prognosis is much
worse compared to patients with a recurrence on the vulva
[5,8,13]. While local recurrences may be controlled with a new
wide local excision and/or radiotherapy, groin recurrences are
usually fatal [13].
The objective of this study was: to analyze patterns and
frequency of recurrences of squamous cell carcinoma of the
vulva after wide local excision and superficial inguinal
lymphadenectomy with separate groin incisions and to
identify prognostic factors for the development of
recurrences.
Patients and methods
Between January 1985 and December 1999, all consecutive 182 patients
with primary vulva cancer, without a previous history of vulvar cancer, were
treated by the same surgeon (M.J.D) and were analyzed for this study: 78 at the
Royal Adelaide Hospital, 54 at the Queen Elizabeth Hospital, 43 at the Attunga
Medical Centre in Adelaide and 7 interstate patients from Darwin. Of 182
patients, five medical records were destroyed and 17 patients had vulvar cancer
with non-squamous cell carcinoma (adenocarcinomas (2), basal cell carcinomas
(5), melanoma (2), sarcoma (1) and 7 other tumors). A total of 160 patients had
primary squamous cell carcinoma. Six of 160 patients received chemoradiation
because of very extensive vulvar cancer, and 29 patients did not have a lymph
node dissection because of extensive vulvar cancer or poor general condition. A
total number of 125 patients were analyzed in the present study.
All patients were staged with the surgical and pathological staging system
for vulvar cancer of the International Federation of Gynecology and Obstetrics
(FIGO 1996) [14]. All patients were treated with wide local excision 1 cm
macroscopically around the tumor, without lymph node dissection in case of a
micro-invasive tumor (invasion <1 mm). In case of a lateral tumor with invasionof >1 mm, patients were treated by wide local excision with unilateral inguinal
lymph node dissection and by wide local excision with bilateral inguinal
lymphadenectomy in case of a midline tumor. All inguinal lymphadenectomies
were performed with separate groin incisions. Radiotherapy (45–50 Gy) was
given to all patients with positive inguinal lymph nodes, unless there was only
one intranodal lymph node metastasis in combination with well differentiated
vulvar cancer. Patients received regular follow-up, every 3 months during the
first 2 years, every 6 months for the subsequent 3 years and then once every
12 months. When a recurrence was diagnosed, the localization of the recurrence
was registered as local, skin bridge, groin or distant. Local recurrences were
treated with wide local excision, whereas recurrences in the groin were treated
with surgery and radiotherapy.
Demographics, medical history, histopathological and clinical data were
obtained from medical records. If not available in medical records, these data
were obtained from the cancer registries of the Royal Adelaide Hospital and the
Queen Elizabeth Hospital. Histopathology reports were retrospectively analyzed
for diameter, depth of invasion, tumor grade, presence of lymph vascular space
involvement or perineural invasion, uni- or multifocality of the tumor, presence
of lichen sclerosis, vulvar intraepithelial neoplasia (VIN) and histopathologic
features such as koilocytosis suspicious for human papilloma virus (HPV)
infection around the tumor, localization of the tumor and free surgical margins of
carcinoma and dysplasia. No central histopathological revisions were made.Statistical methods
Endpoints for this study were: local recurrences, skin bridge
recurrences, groin recurrences and distant recurrences. The
progression-free survival was defined as the time from the date
of primary treatment to the date of diagnosis of first recurrence,
the end of life or last date of follow-up. All clinical and
histopathological factors included in this study (for an overview,
see Table 4) were related to any recurrence risk. Univariate Cox
regression analyses were performed for each prognostic factor
separately, considering local recurrences and other recurrences.
Hazard ratios (HR) and 95% confidence intervals (95%-C.I.)
were estimated. Multivariate Cox regression analyses were
performed including all factors with a hazard ratio in the
univariate model exceeding the value of 1.3. With these
variables, a model was constructed by using a stepwise
procedure. To test the assumption of proportional hazards, an
interaction term of a prognostic variable and a time-dependent
covariate was added [15]. A significant effect of that interaction
term denotes the presence of a time-dependent effect and thus a
violation of the proportional hazards assumption. P values less
than 0.05 were considered to be statistically significant. All
analyses were performed with program SPSS version 12.01.
Results
Primary treatment and staging
The median age of 125 patients at the time of the primary
diagnosis was 72 years (range 23–91 years). (See Table 1 for
an overview of patient characteristics.) Lichen sclerosis was
observed in 62 (50%) patients. VIN was observed in 89
(71%) of the patients. In 38 (30%) patients, lichen sclerosis
and VIN were present. The median age of patients with lichen
sclerosis was 72 years (range 31–90 years) and for patients
with VIN 72 years (range 26–90 years) (data not in table). In
96 of 125 (77%) patients, bilateral lymph node dissection by
Table 1
Patients treated with wide local excision with or without lymph node dissection
with separate groin incisions: characteristics of primary vulva cancer
Patients (n = 125)








No lymph node dissection 15 (12%)
Unilateral lymphadenectomy 14 (11%)





Characteristics of follow-up and recurrences in 125 patients with primary vulvar
cancer
Patients (n = 125)
First recurrences
Local 29 (23%)
Skin bridge 0 (0%)
Groin 11 (9%)
Distant 4 (3%)
Second local recurrence after first local recurrence (n = 29)
Yes 21 (72%)
No 8 (28%)
Third local recurrence after second local recurrence (n = 21)
Yes 12 (57%)
No 9 (43%)
Overall median follow-up 42 (range 1–184 months)
Median interval primary therapy to
recurrence in months
22 (range 3–141 months)
Median interval to first local recurrence 40 (range 3–141 months)
Median interval to first groin recurrence 11 (range 4–42 months)
Overall relapse-free survival at 5 years 58%
Local relapse-free survival at 5 years 70%
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underwent unilateral lymph node dissection. In 15 (12%) pa-
tients with stage IA carcinoma, no lymph node dissection was
performed. In 109 (87%) patients, the margins were free of
tumor after wide local excision and 16 (13%) patients had tumor
positive margins, of which 6/16 (38%) received postoperative
radiotherapy while 9/16 (62%) received a re-excision.
A total of 49 (39%) patients were diagnosed with a T1N0M0
tumor, 42 (33%) with a T2N0M0 tumor, 6 (5%) with a T1N1M0
tumor, 16 (13%) with a T2N1M0 tumor and 12 (10%) patients
were diagnosed with a T2N2M0 tumor of the vulva (Table 2).
Recurrences
Recurrent disease was diagnosed in 44 (35%) patients (Table
3). Local recurrent disease was diagnosed in 29 (23%) patients
and was treated with wide local excision in 27/29 patients and in
2/29 patients with a wide local excision followed by radio-
therapy. A second local recurrence or second primary tumor
developed in 21 (72%) of 29 patients. In this group, most
patients had other epithelial abnormalities. Fifteen (71%)
patients had lichen sclerosis, and 15 (71%) of the patients had
VIN. There were no recurrences in the skin bridge. The upper
confidence bound is (t0: n = 125: 95%-C.I.r: 0.03; t5 n = 43:
95%-C.I.r: 0.09. The median interval from first to second
recurrence was 10 months (range 2–32 months). Of these 21
patients, 15 were again treated with wide local excision, 1
patient was treated with radiotherapy and in 5 patients theTable 2
TNM and FIGO classification of primary vulva cancer (n = 125)
TNM No. (%) FIGO No. (%)
T1N0M0 49 (39%) IA 15 (12%)
T1N1M0 6 (5%) IB 34 (27%)
II 42 (34%)
T2N0M0 42 (33%) III 22 (18%)
T2N1M0 16 (13%) IVA 12 (9%)
T2N2M0 12 (10%)treatment was unknown. In 12 (57%) of the 21 patients with a
second local recurrence, three or more local recurrences were
diagnosed. The site of the local recurrence was not analyzed.
Local recurrences can be a recurrence at the same site as well as
a second primary tumor (tumor de novo) on the contralateral site
of the vulva, especially in patients with premalignant vulvar
disease which was common in this study.
Groin recurrences were diagnosed in 11/125 (9%) patients.
In six (5%) patients with negative lymph nodes at primary
treatment, a groin recurrence was diagnosed. In four of six
patients, bilateral groin dissection was performed, one of six
underwent unilateral groin dissections while one of six patients
did not have lymph node dissection because of stage IA vulvar
cancer. Of 11 patients with groin recurrences, three received
radiotherapy, two patients received surgery and radiotherapy,
two patients received chemotherapy and the treatment of four
patients was unknown. Of 11 patients with a groin recurrence,
10 died of vulvar cancer while 1 patient died of intercurrent
disease. The number of removed lymph nodes was analyzed. In
patients without a groin recurrence, the mean number of
removed lymph nodes was 16 (range 3–35). In patients who
developed a groin recurrence after negative lymph nodes, the
mean number of removed lymph nodes was 13 (range 3–19).
This difference is not significant (t = 1,74: df = 90: P = 0.09).
Distant recurrences were diagnosed in four patients. All patients
with distant recurrences were treated with chemotherapy. They
all died of vulvar cancer.
The overall median follow-up time was 42 months (range 1–
184 months). In 12 (10%) patients, the follow-up was less than
6 months, 2/12 (17%) died of vulvar cancer within 6 months, 3/
12 (25%) died of intercurrent disease and 7/12 (58%) were lost
to follow-up. The median interval from initial therapy to first
recurrence was 22 months (range 3–141 months). Patients with
tumors that recurred in the vulva had a longer median interval to
recurrence of 40 months (range 3–141 months), compared to
296 J.M. Woolderink et al. / Gynecologic Oncology 103 (2006) 293–299these with recurrences to the groin with an interval of 11 months
(range 4–42 months) (Fig. 1).
The local relapse-free survival was 70% at 5 years; the
overall relapse-free survival was 58% at 5 years.
Clinical and histopathological characteristics related to any
recurrence
Multifocality of the primary tumor was more often present in
patients with local recurrences (Table 4). In 41% of the patients
who developed a local recurrence, a multifocal disease was
diagnosed instead of 25% of the patients without a recurrence.
Lichen sclerosis was more often present in patients who
developed local or groin recurrences. A total of 42% of the
patients without a recurrence had lichen sclerosis whether 66%
(local) and 64% (groin) of the patients who developed a
recurrence had lichen sclerosis.
Univariately, age >74 years was the main risk factor for
developing local recurrences (HR: 1.93; 95%-C.I.: 0.92–4.07,
see Table 5). Univariately, differentiation grade, multifocality,
lichen sclerosis and VIN around the tumor were not significant
for developing a local recurrence (respectively HR: 2.10; 95%-
C.I.: 0.86–5.12; HR: 1.27; 95%-C.I.: 0.37–4.34; HR: 1.76;
95%-C.I.: 0.84–3.71; HR: 1.55; 95%-C.I.: 0.72–3.34; HR: 1.40;
95%-C.I.: 0.56–3.45, see Table 5), however, these factors
showed a trend and were used in multivariate analysis.
Multivariately, age >74 years was the only independent
prognostic factor for local recurrences (HR: 2.38; 95%-C.I.:
1.08–5.23, see Table 6).
A risk factor for groin or distant recurrences in univariate
analysis was positive lymph nodes (HR: 3.12; 95%-C.I.: 1.05–
9.29, see Table 5). Multifocality, lymph vascular spaceFig. 1. Development of locainvolvement, perineural invasion and FIGO stage (respectively
HR: 1.26; 95%-C.I.: 0.40–3.97; HR: 2.08; 95%-C.I.: 0.47–
9.24; HR: 3.33; 95%-C.I.: 0.94–11.85; HR: 2.59; 95%-C.I.:
0.94–7.16, see Table 5) showed a trend and were also analyzed
in multivariate analysis. Multivariately, stage III/IV was the
only independent prognostic risk factor for groin or distant
recurrences (HR: 3.03; 95%C.I.: 1.0–9.18). Because positive
lymph nodes were a linearly dependent covariate with stage,
positive lymph nodes was not included in the multivariate
analysis. In the Cox regression model, there was no violation of
the assumption of proportional hazards regarding the two
outcomes and any prognostic factor (data not shown).
Discussion and conclusions
In this retrospective analysis of vulvar cancer patients, none
developed a skin bridge recurrence after wide local excision and
superficial inguinal lymphadenectomy with separate groin
incisions. Although skin bridge recurrences mostly develop in
patients with positive lymph nodes [16], other studies reported
patients with negative nodes who developed a recurrent tumor
in the skin bridge as well [8,10–12,17]. Our data are in
accordance with others who also did not find any skin bridge
recurrence after modifications in the treatment of patients with
vulvar cancer [18–20]. Ansink et al. [7] reported a low
frequency (<1%) of skin bridge recurrences based on pooling of
limited data, suggesting that the use of separate incisions in
patients without suspicious inguinal lymph nodes at palpation is
supposed to be safe.
In our study, 29 patients developed one or more local
recurrences. This is in accordance with the 15–35% as reported
in literature with modified surgical treatment. Piura et al. andl and groin recurrences.
Table 4





























Lateral 79% 83% 82% 50%
Clitoris 17% 14% 18% 50%
Perineum 3% 3% – –



























Well 36% 25% 55% –
Moderate 40% 61% 45% 75%
Poor 24% 14% – 25%
Multifocality




Present 6% 3% 9% 25%
Perineural
invasion
Present 5% – 9% 25%
Lichen sclerosis
Present 42% 66% 64% 25%
VIN/CIS around
tumor
Present 67% 79% 64% 50%
HPV
Present 9% 7% 9% –
Free margins
Present 85% 90% 100% 75%
Free margins
VIN
Present 80% 66% 100% 100%
Stadium
I/II 73% 76% 55% 50%
III/IV 27% 24% 45% 50%
Lymph nodes c
Negative 71% 68% 56% 25%
Positive 29% 32% 44% 75%
a Only available in 98 patients.
b Only available in 123 patients, 80 without a recurrence, 28 with a local
recurrence, 11 with a groin recurrence and 4 with a distant recurrence.
c Only available in 112 patients, 77 without a recurrence, 22 with a local
recurrence, 9 with a groin recurrence, 4 with a distant recurrence (13 patients did
not have lymph node dissection).
Table 5
Clinical and histopathological characteristics related to outcomes: univariate





recurrence (n = 29) a
With a groin or distant
recurrence (n = 15) a
Age in years
<75 years 1 1
>/=75 years 1.93 (0.92–4.07) b 1.57 (0.57–4.35
Localization of tumor
Lateral 1 1
Clitoris, perineum, vagina 0.97 (037–2.56) 1.55 (0.49–4.87)
Maximum Ø of the tumor
in mm
1.0 (0.98–1.02) 1.0 (0.98–1.03)
Maximum invasion depth
in mm
0.98 (0.81–1.19) 1.31 (0.91–1.88)
Differentiation grade
Well 1 1
Moderate 2.10 (0.86–5.12) b 1.15 (0.40–3.27)
Poor 1.27 (0.37–4.34) b 0.32 (0.04–2.62)
Multifocality
No 1 1




Yes 0.73 (0.10–5.35) 2.08 (0.47–9.24) b
Perineural invasion
No – 1
Yes 3.33 (0.94–11.85) b
Lichen sclerosis
No 1 1
Yes 1.55 (0.72–3.34) b 1.52 (0.54–4.27)
VIN/CIS around the tumor
No 1 1
Yes 1.40 (0.56–3.45) b 2.01 (0.57–7.16)
HPV
No 1 1
Yes 0.72 (0.17–3.06) 0.76 (0.10–5.82)
Free margins
Yes 1 1






III/IV 1.10 (0.47–2.60) 2.59 (0.94–7.16) b
Lymph nodes
Negative 1 1
Positive 1.38 (0.56–3.39) 3.12 (1.05–9.29) c
a Compared to patients without a recurrence (n = 81).
b These variables were used in multivariate analysis.
c Because positive lymph nodes were a linearly dependent covariate with
stage, positive lymph nodes were not included in the multivariate analysis.
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and 21% in 238 patients, and Cavanagh et al. gave an overview
of studies and reported recurrences in 15–40% of which 55–
90% were local recurrences [21–23]. Wide local excision leavespart of the possible abnormal vulva in situ. These vulvar
abnormalities can become a local recurrence or a second
primary tumor. A certain amount of local recurrences are second
primaries (tumor de novo) especially after a long interval.
However, of 29 patients, 21 (72%) developed a second local
recurrence after a median interval of 10 months and in 12 of 21
(57%) patients 3 or more local recurrences were diagnosed.
Table 6
Clinical and histopathological characteristics related to outcomes: multivariate
analysis (HR (95% confidence intervals)) (n = 110 a)
Clinical and histopathological characteristics With a local recurrence (n = 29)
















a A comparison between patients without a recurrence and with a local
recurrence.
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recurrence, and a close follow-up is necessary in these patients.
These local recurrences had no negative effect on the survival
for none of the patients died of vulvar cancer. No pathology
revision was performed in this study, and therefore histological
margins could not be analyzed. de Hullu et al. [8] reported that
surgical margins measuring 1 cm which was performed in this
study resulted in histological margins measuring≤8 mm in 50%
of patients leading to a higher local recurrence rate.
Eleven patients developed a groin recurrence after superficial
inguinal lymph node dissection. Six (5%) patients with negative
lymph nodes in primary treatment developed a groin recurrence.
One patient did not have lymph node dissection because of
stage IA vulvar cancer. In literature, unexpected groin relapses
were found in 5–7% of patients with negative inguinofemoral
lymph nodes after inguinofemoral lymphadenectomy by
separate incisions [8,24,25], which appears to be a substantial
increase in the number of groin recurrences compared with the
en bloc approach [8,26]. Gordenier et al. [27] and Katz et al.
[28] also found 9% and 16% groin recurrences. Kirby et al. [29]
found a groin recurrence rate of 4.6% in 65 stage I/II vulvar
cancers after inguinal lymphadenectomy. In these studies,
however, only superficial inguinal lymph node dissection was
performed as we did. Superficial inguinal lymph node
dissection instead of deep inguinofemoral lymph node dissec-
tion may have increased the number of patients with lymph
node recurrences also in our series as shown in literature [30]
and should be replaced by inguinofemoral lymphadenectomy.
Groin relapse in patients who had negative nodes at superficial
inguinal lymphadenectomy in our series occurred in six
patients, and it carried a very poor prognosis. Most patients
with groin recurrence die of disease [31]. In our series, 10 of 11
patients with groin recurrences died of disease.
Patients over 74 years were at higher risk for developing a
local recurrence than younger patients. In this group of patients,
there was a trend towards more lichen sclerosis and of courselichen sclerosis was not completely removed by wide local
excision. Although we do not have pathological information
about the histological margins, it might be that older patients got
less extensive treatment because of co-morbidity.
As expected, patients with FIGO stage III/IV showed a
significant higher risk for developing a groin or distant
recurrence in this study. All patients in this study with FIGO
stage III/IV had positive lymph nodes. This is in accordance
with others who also found positive lymph nodes as a predictive
factor [21,32,33]. The primary route of spread in vulvar cancer
is by lymphatic embolization to the regional inguinofemoral
lymph nodes. Especially the number of positive lymph nodes
and extra-nodal tumor growth are of great importance for the
prognosis of the patient [31,34].
Conclusion: In this large study of vulvar cancer patients after
introduction of modified surgical treatment, wide local excision
and superficial inguinal lymphadenectomy with separate
incisions lead to a local recurrence rate of 23%, a groin
recurrence rate of 9% and no recurrences in the skin bridge.
Superficial inguinal in stead of deep inguinofemoral lympha-
denectomy may have increased the number of patients with
lymph node recurrences also in our series and should be
replaced by the latter. Of all patients with a local recurrence,
72% developed second or more local recurrences; this group of
patients needs a close follow-up.
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